Health care is moving towards smart online devices such as wearables with smart phone apps for monitoring. In the same way that a Fitbit measures activity, people are now able to observe their heart rate and respiratory rate throughout the day. This InnoCentive Challenge attempts to harness the excitement around the technology of online monitoring and apply this technology to drug research and development. Our aspirations include measuring drug concentrations and markers of drug efficacy and toxicity. Such online longitudinal measurement of small molecules (e.g. testosterone, estrogens, corticosteroids, and acetaminophen) has the potential to impact the way that pharmacology and toxicology is investigated in preclinical drug discovery. The advantage would be to gain much more information from each experiment. Current studies, both preclinically and in our patients, are restricted by access to tissue biopsies, timing of such biopsies, and limitation on blood draws. There are already examples of online monitoring sensors for specific molecules, such as glucose, being used in the clinic to great effect. We want to access a generic device that can allow longitudinal measurement of the concentrations of multiple small molecules in blood and other tissues.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.
Successful new medicines provide therapeutic benefit with minimum side effects. Before our clinical trials, we would like to assess the therapeutic and toxic potential of new medicines in predictive animal models. We are currently limited in the extent of longitudinal data that can be gathered as well as the number of analytes that can be measured. Unfortunately, this limits our understanding of the pharmacology of new medicines. We seek a technology that can provide a solution to this gap in our current technologies and improve the development of new medicines.
There are technologies available that are moving towards continuous online measurement but they have been optimized for one analyte (e.g. glucose) and are not sufficiently small to be used with animals. AstraZeneca desires a solution that provides a new implantable or wearable measurement technology that meets our technical requirements of providing real-time measurements over a week and wireless transmission of data.
This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (maximum of 10 pages, including supporting non-confidential information and contact details) to be evaluated by AstraZeneca with a goal of establishing a collaborative partnership. Upon completion of the evaluation, AstraZeneca may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed upon time frame.
[NOTE: Only proposals from Solvers who have the ability to work as the collaboration partner will be considered.]
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on January 17, 2017.
Late submissions will not be considered.
ABOUT THE SEEKER
AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular and metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research.
What is an eRFP Challenge?
eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.
After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.
This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.